

Resource Summary Report

Generated by [RRID](#) on Aug 2, 2026

p53 (1C12) Mouse mAb (Alexa Fluor 647 Conjugate)

RRID:AB_2256294

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2533, RRID:AB_2256294

Antibody Information

URL: http://antibodyregistry.org/AB_2256294

Proper Citation: Cell Signaling Technology Cat# 2533, RRID:AB_2256294

Target Antigen: p53 (1C12) Mouse mAb (Alexa Fluor 647 Conjugate)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: F. Consolidation on 10/2018: AB_10693443, AB_2256294.

Antibody Name: p53 (1C12) Mouse mAb (Alexa Fluor 647 Conjugate)

Description: This monoclonal targets p53 (1C12) Mouse mAb (Alexa Fluor 647 Conjugate)

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_2256294

Vendor: Cell Signaling Technology

Catalog Number: 2533

Record Creation Time: 20250820T020431+0000

Record Last Update: 20250820T123755+0000

Ratings and Alerts

No rating or validation information has been found for p53 (1C12) Mouse mAb (Alexa Fluor 647 Conjugate).

No alerts have been found for p53 (1C12) Mouse mAb (Alexa Fluor 647 Conjugate).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ingelshed K, et al. (2024) MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors. *iScience*, 27(6), 109862.

Zaher DM, et al. (2021) A Novel Benzopyrane Derivative Targeting Cancer Cell Metabolic and Survival Pathways. *Cancers*, 13(11).

Rosu A, et al. (2021) Loss of tRNA-modifying enzyme Elp3 activates a p53-dependent antitumor checkpoint in hematopoiesis. *The Journal of experimental medicine*, 218(3).

Zhu X, et al. (2019) Noc4L-Mediated Ribosome Biogenesis Controls Activation of Regulatory and Conventional T Cells. *Cell reports*, 27(4), 1205.

Sharma MD, et al. (2018) Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. *Immunity*, 48(1), 91.